Case and Research Letter
Oral Oxybutynin for Local and Multifocal Hyperhidrosis: A Multicenter Study
Estudio multicéntrico sobre el uso de oxibutinina oral en hiperhidrosis local y multifocal
Read
5719
Timeswas read the article
1932
Total PDF
3787
Total HTML
Share statistics
array:24 [ "pii" => "S1578219017301427" "issn" => "15782190" "doi" => "10.1016/j.adengl.2017.05.001" "estado" => "S300" "fechaPublicacion" => "2017-07-01" "aid" => "1574" "copyright" => "Elsevier España, S.L.U. and AEDV" "copyrightAnyo" => "2016" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Actas Dermosifiliogr. 2017;108:597-9" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 593 "formatos" => array:3 [ "EPUB" => 33 "HTML" => 438 "PDF" => 122 ] ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0001731016304434" "issn" => "00017310" "doi" => "10.1016/j.ad.2016.11.013" "estado" => "S300" "fechaPublicacion" => "2017-07-01" "aid" => "1574" "copyright" => "AEDV" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Actas Dermosifiliogr. 2017;108:597-9" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 428 "formatos" => array:3 [ "EPUB" => 4 "HTML" => 317 "PDF" => 107 ] ] "es" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Carta científico-clínica</span>" "titulo" => "Estudio multicéntrico sobre el uso de oxibutinina oral en hiperhidrosis local y multifocal" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "597" "paginaFinal" => "599" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Oral Oxybutynin for Local and Multifocal Hyperhidrosis: A Multicenter Study" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2031 "Ancho" => 2663 "Tamanyo" => 126470 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Agrupación de casos antes-después según respuesta al HDSS (número de casos con determinado HDSS antes del tratamiento, sector izquierdo; después, sector derecho).</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "T. Toledo-Pastrana, J. Márquez-Enríquez, J.F. Millán-Cayetano" "autores" => array:3 [ 0 => array:2 [ "nombre" => "T." "apellidos" => "Toledo-Pastrana" ] 1 => array:2 [ "nombre" => "J." "apellidos" => "Márquez-Enríquez" ] 2 => array:2 [ "nombre" => "J.F." "apellidos" => "Millán-Cayetano" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S1578219017301427" "doi" => "10.1016/j.adengl.2017.05.001" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219017301427?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731016304434?idApp=UINPBA000044" "url" => "/00017310/0000010800000006/v3_201707250313/S0001731016304434/v3_201707250313/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S1578219017302081" "issn" => "15782190" "doi" => "10.1016/j.adengl.2016.11.021" "estado" => "S300" "fechaPublicacion" => "2017-07-01" "aid" => "1604" "copyright" => "Elsevier España, S.L.U. and AEDV" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Actas Dermosifiliogr. 2017;108:599-601" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 360 "formatos" => array:3 [ "EPUB" => 31 "HTML" => 258 "PDF" => 71 ] ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Case and Research Letter</span>" "titulo" => "Sorafenib-induced Acute Generalized Exanthematous Pustulosis: An Increasing Association?" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "599" "paginaFinal" => "601" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Pustulosis exantemática generalizada aguda por sorafenib: ¿una relación en aumento?" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 773 "Ancho" => 3167 "Tamanyo" => 259430 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Clinical evolution. (a) Exanthema affecting mainly face, upper trunk, superior limbs with isolated patches on abdomen and lower extremities. (b) Closer image showing isolated pustules surrounded by erythema. (c) Evolution of the exanthema 5 days after Sorafenib discontinuation. Mild erythema and desquamation on upper trunk with pustules resolution.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "A. Alegre-Sánchez, D. de Perosanz-Lobo, I. Pinilla-Pagnon, E. Muñoz-Zato" "autores" => array:4 [ 0 => array:2 [ "nombre" => "A." "apellidos" => "Alegre-Sánchez" ] 1 => array:2 [ "nombre" => "D." "apellidos" => "de Perosanz-Lobo" ] 2 => array:2 [ "nombre" => "I." "apellidos" => "Pinilla-Pagnon" ] 3 => array:2 [ "nombre" => "E." "apellidos" => "Muñoz-Zato" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S0001731017300601" "doi" => "10.1016/j.ad.2016.11.018" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731017300601?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219017302081?idApp=UINPBA000044" "url" => "/15782190/0000010800000006/v1_201706300050/S1578219017302081/v1_201706300050/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S1578219017301439" "issn" => "15782190" "doi" => "10.1016/j.adengl.2017.05.002" "estado" => "S300" "fechaPublicacion" => "2017-07-01" "aid" => "1575" "copyright" => "Elsevier España, S.L.U. and AEDV" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Actas Dermosifiliogr. 2017;108:595-7" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 691 "formatos" => array:3 [ "EPUB" => 40 "HTML" => 555 "PDF" => 96 ] ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Case and Research Letters</span>" "titulo" => "Periarticular Thenar Erythema and Onycholysis Syndrome: A Manifestation of Taxane-Induced Cutaneous Toxicity" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "595" "paginaFinal" => "597" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Síndrome de eritema tenar periarticular y onicolisis: una manifestación de toxicidad cutánea por taxanos" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1266 "Ancho" => 950 "Tamanyo" => 369100 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Histology of the lesion on the dorsum of the hand of patient<span class="elsevierStyleHsp" style=""></span>2. A, Hyperkeratotic epidermis with parakeratosis, foci of vacuolar degeneration of the basal layer, and a band-like perivascular infiltrate with occasional eosinophils. Hematoxylin and eosin, original magnification ×10. B, At higher power, evidence of necrotic keratinocytes in the epidermis. Hematoxylin and eosin, original magnification<span class="elsevierStyleHsp" style=""></span>×40.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "E. Rodríguez-Lomba, I. Molina-López, R. Suárez-Fernández, O. Baniandrés-Rodríguez" "autores" => array:4 [ 0 => array:2 [ "nombre" => "E." "apellidos" => "Rodríguez-Lomba" ] 1 => array:2 [ "nombre" => "I." "apellidos" => "Molina-López" ] 2 => array:2 [ "nombre" => "R." "apellidos" => "Suárez-Fernández" ] 3 => array:2 [ "nombre" => "O." "apellidos" => "Baniandrés-Rodríguez" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731016304446" "doi" => "10.1016/j.ad.2016.11.014" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731016304446?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219017301439?idApp=UINPBA000044" "url" => "/15782190/0000010800000006/v1_201706300050/S1578219017301439/v1_201706300050/en/main.assets" ] "en" => array:16 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Case and Research Letter</span>" "titulo" => "Oral Oxybutynin for Local and Multifocal Hyperhidrosis: A Multicenter Study" "tieneTextoCompleto" => true "saludo" => "<span class="elsevierStyleItalic">To the Editor</span>," "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "597" "paginaFinal" => "599" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "T. Toledo-Pastrana, J. Márquez-Enríquez, J.F. Millán-Cayetano" "autores" => array:3 [ 0 => array:4 [ "nombre" => "T." "apellidos" => "Toledo-Pastrana" "email" => array:1 [ 0 => "ttoledop@gmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "J." "apellidos" => "Márquez-Enríquez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "J.F." "apellidos" => "Millán-Cayetano" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] ] "afiliaciones" => array:3 [ 0 => array:3 [ "entidad" => "Servicio de Dermatología, Hospital Universitario Donostia, San Sebastián, Guipúzcoa, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Unidad de Gestión Clínica de Medicina Interna-Dermatología, Hospital de Jerez, Jerez de la Frontera, Cádiz, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Servicio de Dermatología, Hospital Costa del Sol, Marbella, Málaga, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Estudio multicéntrico sobre el uso de oxibutinina oral en hiperhidrosis local y multifocal" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2031 "Ancho" => 2663 "Tamanyo" => 124725 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Numbers of patients with given Hyperhidrosis Disease Severity Scale (HDSS) scores before (left) and after (right) treatment.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Although the psychosocial consequences of hyperhidrosis are well known, the impact of this disease has traditionally been underestimated by the medical community. Oxybutynin chloride is an effective, safe, and well-tolerated treatment for hyperhidrosis that has been increasingly used since 2006. Most authors recommend a starting dose of 2.5<span class="elsevierStyleHsp" style=""></span>mg/d and a maximum dose of 15<span class="elsevierStyleHsp" style=""></span>mg/d. The safety of oxybutynin has been demonstrated in patients with hyperhidrosis.<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">1</span></a> However, despite its effectiveness, favorable adverse effect profile, and affordable price, this drug is not as widely used as would be expected.</p><p id="par0010" class="elsevierStylePara elsevierViewall">We present a series of 56 patients with primary hyperhidrosis treated with oxybutynin (5-mg tablets) at 5 Spanish hospitals between May 2013 and February 2016. The patients began by taking half a tablet at breakfast and another half at lunchtime for a week. When this dosage did not achieve control of the sweating, the daily dose was increased by 2.5<span class="elsevierStyleHsp" style=""></span>mg and maintained for a week. This increase was repeated weekly until a maximum dose of 15<span class="elsevierStyleHsp" style=""></span>mg/d was reached.</p><p id="par0015" class="elsevierStylePara elsevierViewall">The following variables were studied: sex, age, hyperhidrosis sites (palms and axillae, soles and axillae, palms and soles), starting dose (5<span class="elsevierStyleHsp" style=""></span>mg in all cases), maintenance dose, adverse effects, and, when reported, the adverse effect that caused the greatest discomfort. Patients aged over 14 years with hyperhidrosis at one or more sites that had not been treated with anything other than topical agents were included. Exclusion criteria were failure to meet the previous criteria, a contraindication for treatment with oral anticholinergics, and previous use of iontophoresis, botulinum toxin, or systemic drugs to treat their condition. All the patients or their legal representatives signed an informed consent form agreeing to the off-label use of oxybutynin.</p><p id="par0020" class="elsevierStylePara elsevierViewall">The patients were assessed with the Hyperhidrosis Disease Severity Scale (HDSS) at the start of treatment and at 3 months (follow-up time: 3 months from treatment initiation). We performed a descriptive analysis of the study variables and a quasi-experimental before-after-type study of changes in HDSS scores using the Wilcoxon rank-sum test. We also performed Probit regression with the aim of establishing the minimum effective dose that produces a beneficial treatment outcome. The statistical analyses were performed in SPSS (v.19.0).</p><p id="par0025" class="elsevierStylePara elsevierViewall">We studied 56 patients (35 females and 21 males) from the following hospitals: Hospital de Jerez (n<span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleMonospace">=</span><span class="elsevierStyleHsp" style=""></span>19), Hospital Universitario Donostia (n<span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleMonospace">=</span><span class="elsevierStyleHsp" style=""></span>12), Hospital Quirón Sagrado Corazón (n<span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleMonospace">=</span><span class="elsevierStyleHsp" style=""></span>10), Hospital Costa del Sol (n<span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleMonospace">=</span><span class="elsevierStyleHsp" style=""></span>8), and Hospital de Día Quirón Donostia (n<span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleMonospace">=</span><span class="elsevierStyleHsp" style=""></span>7). The mean age of the patients was 23.54 years (range, 14-37 years). The affected sites were the palms and axillae in 37 patients, the palms and soles in 13, and the soles and axillae in 6. No significant differences were found between the different sites in patients who responded to treatment. The most frequently used maintenance dose was 10<span class="elsevierStyleHsp" style=""></span>mg/d (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>).</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0030" class="elsevierStylePara elsevierViewall">Forty-eight patients (85.71%) showed an improvement, which was defined as a reduction in HDSS score of at least 2 points (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>), 7 (12.5%) showed no change, and 1 (1.79%) showed worsening. No adverse effects were reported for 43 (76.87%) of the patients. The most common adverse effect (reported in 10.5% of cases) was a “sensation of medicalization” related to having to take the drug every 8<span class="elsevierStyleHsp" style=""></span>hours, although strictly speaking, this would be an inconvenience rather than an adverse effect. The next most common effects reported were xerosis (n<span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleMonospace">=</span><span class="elsevierStyleHsp" style=""></span> 6), nausea (n<span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleMonospace">=</span><span class="elsevierStyleHsp" style=""></span>2), headache (n<span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleMonospace">=</span><span class="elsevierStyleHsp" style=""></span>1), constipation (n<span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleMonospace">=</span><span class="elsevierStyleHsp" style=""></span>1), and acute urine retention (n<span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleMonospace">=</span><span class="elsevierStyleHsp" style=""></span>1). No statistically significant differences were observed in the Probit model, and we were therefore unable to estimate a minimum dose after which to expect desired treatment effects or adverse effects.</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0035" class="elsevierStylePara elsevierViewall">Until recently, oral anticholinergics were used only in patients with hyperhidrosis that proved refractory to other treatments,<a class="elsevierStyleCrossRefs" href="#bib0035"><span class="elsevierStyleSup">2,3</span></a> even though they are a safe and well-tolerated option. The adverse effect that caused the greatest discomfort in our series was the sensation of medicalization, felt by many patients in relation to having to indefinitely take half a tablet or a full tablet every 8 or 12<span class="elsevierStyleHsp" style=""></span>hours. As with xerosis, this effect can be controlled by taking a single dose at night.<a class="elsevierStyleCrossRefs" href="#bib0045"><span class="elsevierStyleSup">4,5</span></a></p><p id="par0040" class="elsevierStylePara elsevierViewall">We have also seen that some patients prefer not to use oxybutynin as maintenance therapy, despite its effectiveness, but rather to take it occasionally, for example when their hyperhidrosis may be less tolerable, such as before a social or work event, or at certain times of the year.</p><p id="par0045" class="elsevierStylePara elsevierViewall">In summary, we consider that oxybutynin is an effective and efficient treatment for primary hyperhidrosis. It causes few adverse effects and can be used as occasional treatment or as maintenance therapy. It should be considered as a possible first-line treatment for patients with focal hyperhidrosis affecting 2 or more sites or for generalized hyperhidrosis. Its price (€4.15 for 60 tablets in May 2016) is another obvious advantage, particularly for public health care systems. Larger series are needed to demonstrate the true value of this drug.</p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Conflicts of Interest</span><p id="par0050" class="elsevierStylePara elsevierViewall">The authors declare that they have no conflicts of interest.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0005" "titulo" => "Conflicts of Interest" ] 1 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Toledo-Pastrana T, Márquez-Enríquez J, Millán-Cayetano JF. Estudio multicéntrico sobre el uso de oxibutinina oral en hiperhidrosis local y multifocal. Actas Dermosifiliogr. 2017;108:597–599.</p>" ] ] "multimedia" => array:2 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2031 "Ancho" => 2663 "Tamanyo" => 124725 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Numbers of patients with given Hyperhidrosis Disease Severity Scale (HDSS) scores before (left) and after (right) treatment.</p>" ] ] 1 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Defined as a decrease in Hyperhidrosis Disease Severity Scale score of at least 2 points with respect to the score before treatment.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">5<span class="elsevierStyleHsp" style=""></span>mg \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">7.5<span class="elsevierStyleHsp" style=""></span>mg \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">10<span class="elsevierStyleHsp" style=""></span>mg \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">12.5<span class="elsevierStyleHsp" style=""></span>mg \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">15<span class="elsevierStyleHsp" style=""></span>mg \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Total \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">17 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">11 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">43 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1450911.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Maintenance Dose in Patients Who Showed Improvement After 3 Months of Treatment With Oxybutynin.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:5 [ 0 => array:3 [ "identificador" => "bib0030" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Tratamiento sistémico de la hiperhidrosis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "J. Del Boz" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ad.2014.11.012" "Revista" => array:6 [ "tituloSerie" => "Actas Dermosifiliogr" "fecha" => "2015" "volumen" => "106" "paginaInicial" => "271" "paginaFinal" => "277" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25638324" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0035" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Nuevas perspectivas en hiperhidrosis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "T. Toledo-Pastrana" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Piel" "fecha" => "2016" "volumen" => "31" "paginaInicial" => "360" "paginaFinal" => "364" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0040" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Oxybutynin as a treatment for generalized hyperhidrosis: A randomized, placebo-controlled trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Schollhammer" 1 => "E. Brenaut" 2 => "N. Menard-Andivot" 3 => "M. Pillette-Delarue" 4 => "A. Zagnoli" 5 => "M. Chassain-Le Lay" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/bjd.13973" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2015" "volumen" => "173" "paginaInicial" => "1163" "paginaFinal" => "1168" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26114588" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0045" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Quality of life before hyperhidrosis treatment as a predictive factor for oxybutynin treatment outcomes in palmar and axillary hyperhidrosis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "N. Wolosker" 1 => "M. Krutman" 2 => "M.P. Teivelis" 3 => "T.P. Campbell" 4 => "P. Kauffman" 5 => "J.R. de Campos" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.avsg.2013.07.032" "Revista" => array:6 [ "tituloSerie" => "Ann Vasc Surg" "fecha" => "2014" "volumen" => "28" "paginaInicial" => "970" "paginaFinal" => "976" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24333527" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0050" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Oral oxybutynin for the treatment of hyperhidrosis: Outcomes after one-year follow-up" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "J.F. Millan-Cayetano" 1 => "J. del Boz" 2 => "F. Rivas-Ruiz" 3 => "N. Blázquez-Sánchez" 4 => "C. Hernández Ibáñez" 5 => "M. de Troya-Martín" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/ajd.12473" "Revista" => array:2 [ "tituloSerie" => "Australas J Dermatol" "fecha" => "2016" ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/15782190/0000010800000006/v1_201706300050/S1578219017301427/v1_201706300050/en/main.assets" "Apartado" => array:4 [ "identificador" => "6157" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Case and Research Letters" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/15782190/0000010800000006/v1_201706300050/S1578219017301427/v1_201706300050/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219017301427?idApp=UINPBA000044" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 11 | 9 | 20 |
| 2024 October | 102 | 48 | 150 |
| 2024 September | 109 | 39 | 148 |
| 2024 August | 114 | 55 | 169 |
| 2024 July | 93 | 38 | 131 |
| 2024 June | 108 | 52 | 160 |
| 2024 May | 84 | 45 | 129 |
| 2024 April | 82 | 50 | 132 |
| 2024 March | 68 | 52 | 120 |
| 2024 February | 68 | 37 | 105 |
| 2024 January | 53 | 39 | 92 |
| 2023 December | 51 | 21 | 72 |
| 2023 November | 95 | 40 | 135 |
| 2023 October | 103 | 34 | 137 |
| 2023 September | 98 | 31 | 129 |
| 2023 August | 77 | 19 | 96 |
| 2023 July | 79 | 30 | 109 |
| 2023 June | 87 | 20 | 107 |
| 2023 May | 64 | 25 | 89 |
| 2023 April | 40 | 24 | 64 |
| 2023 March | 55 | 24 | 79 |
| 2023 February | 48 | 34 | 82 |
| 2023 January | 46 | 23 | 69 |
| 2022 December | 63 | 26 | 89 |
| 2022 November | 32 | 26 | 58 |
| 2022 October | 45 | 19 | 64 |
| 2022 September | 28 | 36 | 64 |
| 2022 August | 25 | 32 | 57 |
| 2022 July | 23 | 29 | 52 |
| 2022 June | 29 | 30 | 59 |
| 2022 May | 53 | 34 | 87 |
| 2022 April | 57 | 33 | 90 |
| 2022 March | 71 | 38 | 109 |
| 2022 February | 56 | 24 | 80 |
| 2022 January | 65 | 37 | 102 |
| 2021 December | 44 | 41 | 85 |
| 2021 November | 102 | 46 | 148 |
| 2021 October | 60 | 50 | 110 |
| 2021 September | 52 | 32 | 84 |
| 2021 August | 29 | 32 | 61 |
| 2021 July | 40 | 36 | 76 |
| 2021 June | 43 | 24 | 67 |
| 2021 May | 56 | 43 | 99 |
| 2021 April | 117 | 88 | 205 |
| 2021 March | 102 | 45 | 147 |
| 2021 February | 63 | 32 | 95 |
| 2021 January | 37 | 22 | 59 |
| 2020 December | 45 | 19 | 64 |
| 2020 November | 36 | 18 | 54 |
| 2020 October | 28 | 12 | 40 |
| 2020 September | 45 | 19 | 64 |
| 2020 August | 29 | 19 | 48 |
| 2020 July | 36 | 17 | 53 |
| 2020 June | 30 | 26 | 56 |
| 2020 May | 20 | 10 | 30 |
| 2020 April | 27 | 14 | 41 |
| 2020 March | 26 | 11 | 37 |
| 2020 February | 4 | 1 | 5 |
| 2020 January | 4 | 0 | 4 |
| 2019 December | 4 | 0 | 4 |
| 2019 November | 2 | 0 | 2 |
| 2019 September | 4 | 0 | 4 |
| 2019 August | 4 | 0 | 4 |
| 2019 July | 4 | 0 | 4 |
| 2019 June | 4 | 0 | 4 |
| 2019 May | 4 | 0 | 4 |
| 2019 April | 2 | 0 | 2 |
| 2019 February | 6 | 0 | 6 |
| 2019 January | 1 | 0 | 1 |
| 2018 December | 4 | 0 | 4 |
| 2018 November | 5 | 0 | 5 |
| 2018 October | 2 | 0 | 2 |
| 2018 September | 2 | 0 | 2 |
| 2018 July | 1 | 0 | 1 |
| 2018 April | 0 | 1 | 1 |
| 2018 February | 40 | 4 | 44 |
| 2018 January | 20 | 7 | 27 |
| 2017 December | 76 | 13 | 89 |
| 2017 November | 20 | 8 | 28 |
| 2017 October | 33 | 10 | 43 |
| 2017 September | 47 | 12 | 59 |
| 2017 August | 57 | 19 | 76 |
| 2017 July | 70 | 28 | 98 |
| 2017 June | 18 | 20 | 38 |
Show all
